New hope for advanced cancer: first human trial of GS-0201 begins

NCT ID NCT06167317

Recruiting now Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 278 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Chaim Sheba Medical Center
RECRUITING

Tel Litwinsky, 52621, Israel
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02459, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Austin
RECRUITING

Austin, Texas, 78758, United States
NEXT Dallas
RECRUITING

Irving, Texas, 75039, United States
Rambam Health Care Campus
RECRUITING

Haifa, 31096, Israel
Tel Aviv Sourasky Medical Center
RECRUITING

Tel Aviv, 6423906, Israel
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.